OncoMatch/Clinical Trials/NCT05779423
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Is NCT05779423 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ipilimumab and Nivolumab for metastatic melanoma.
Treatment: Ipilimumab · Nivolumab — The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (an immunotherapy)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: checkpoint inhibitor (pembrolizumab, nivolumab, nivolumab-relatimab, atezolizumab, ipilimumab)
progressed on immune checkpoint inhibitor therapy (pembrolizumab, nivolumab, nivolumab-relatimab, atezolizumab, ipilimumab)
Cannot have received: combination checkpoint inhibitor (ipilimumab, nivolumab)
Exception: if combination was the last line of therapy and patient is progressing
Participants who are progressing on combination ipilimumab/nivolumab as their last line of therapy
Lab requirements
Blood counts
Leukocytes ≥3,000/mcL; Absolute neutrophil count ≥1,000/mcL; Platelets ≥75,000/mcL
Kidney function
CrCL > 30 ml/min
Liver function
Total bilirubin ≤3 institutional ULN; AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN
Participants must have adequate organ and marrow function as defined below: * Leukocytes ≥3,000/mcL * Absolute neutrophil count ≥1,000/mcL * Platelets ≥75,000/mcL * Total bilirubin ≤3 institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN * CrCL > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05779423 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior combination checkpoint inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages